Cargando…

Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease which regulates serum low-density lipoprotein cholesterol (LDL-C) levels by promoting the degradation of the hepatic low-density lipoprotein receptor (LDLR), and has become an attractive therapeutic target for cholesterol low...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Lili, Wang, Yue, Xu, Yaqiong, Tian, Qinghua, Lei, Gaoxin, Zhao, Cheng, Gao, Zhan, Pan, Qin, Zhao, Wenfeng, Nong, Liu, Tan, Shuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655242/ https://www.ncbi.nlm.nih.gov/pubmed/29113347 http://dx.doi.org/10.18632/oncotarget.20590

Ejemplares similares

Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE(−/−) Mice
por: Gu, Lili, et al.
Publicado: (2019)

Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling
por: Qian, Zhengyao, et al.
Publicado: (2022)

Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA
por: Bjune, Katrine, et al.
Publicado: (2018)

Testosterone Deficiency Promotes Hypercholesteremia and Attenuates Cholesterol Liver Uptake via AR/PCSK9/LDLR Pathways
por: Yuefeng, Yu, et al.
Publicado: (2022)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
por: Gupta, Nidhi, et al.
Publicado: (2010)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
por: Luna Saavedra, Yascara Grisel, et al.
Publicado: (2013)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2020)

Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance
por: Lebeau, Paul F., et al.
Publicado: (2022)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2021)

Platycodin D enhances LDLR expression and LDL uptake via down-regulation of IDOL mRNA in hepatic cells
por: Choi, Yu-Jeong, et al.
Publicado: (2020)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a
por: Cui, Chuan-Jue, et al.
Publicado: (2020)

Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture
por: Mbikay, Majambu, et al.
Publicado: (2014)

In Silico Insights into Protein–Protein Interaction Disruptive Mutations in the PCSK9-LDLR Complex
por: Martin, William R., et al.
Publicado: (2020)

Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function
por: Sabovic, Iva, et al.
Publicado: (2023)

A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
por: Safarova, Maya S., et al.
Publicado: (2019)

The Sirt1 activator SRT3025 provides atheroprotection in Apoe(−/−) mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression
por: Miranda, Melroy X., et al.
Publicado: (2015)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Gustafsen, Camilla, et al.
Publicado: (2017)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
por: Futema, Marta, et al.
Publicado: (2014)

LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers
por: Ochoa, Eguzkine, et al.
Publicado: (2016)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis
por: Shi, Xiangguang, et al.
Publicado: (2022)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

Back to Basics: PCSK9 as a New Target for the LDL Receptor
por: Corral, Pablo
Publicado: (2014)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

γGT and PCSK9 variants in subjects with hyper-LDL-cholesterolemia
por: Hamasaki, Masato, et al.
Publicado: (2022)

Acaudina molpadioides mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells
por: Jack, Allicia, et al.
Publicado: (2021)

Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine
por: De Castro-Orós, Isabel, et al.
Publicado: (2016)

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro
por: Li, Li, et al.
Publicado: (2018)

23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9
por: Li, Hui-hui, et al.
Publicado: (2019)

Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis
por: Wu, Yue, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_72fhjf61tgj0he4iio9m9nsvgf